Biopatch Protective Disk with CHG meets the updated CDC recommendation requirements, and continues as the standard of care for reducing intravascular catheter-related blood stream infections.
Biopatch is the only IV dressing proven in multiple meta-analyses and randomized controlled trials to reduce risk of central line associated bloodstream infections in patients with central and arterial lines.
The new CDC guideline says: "For patients aged 18 years and older: Chlorhexidine-impregnated dressings with an FDA-cleared label that specifies a clinical indication for reducing catheter-related bloodstream infection (CRBSI) or catheter-associated bloodstream infection (CABSI) are recommended to protect the insertion site of short-term, non-tunneled central venous catheters."
Ethicon, part of the Johnson and Johnson Medical Devices Companies, is dedicated to addressing pressing health care issues to improve and save lives. Its surgical technologies and solutions, include sutures, staplers, energy devices, trocars, hemostats, and infection prevention solutions.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project